TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...

REHOVOT, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

Houlihan Lokey's Rainer Hepberger sees a busy deal pipeline, with numerous live transactions and pitch activities.

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted ...